Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer
Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 9(2009), 10 vom: 01. Dez., Seite 1058-69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sissung, Tristan M [VerfasserIn] |
|---|
| Themen: |
4Z8R6ORS6L |
|---|
| Anmerkungen: |
Date Completed 05.11.2010 Date Revised 20.10.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM191037249 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM191037249 | ||
| 003 | DE-627 | ||
| 005 | 20231223190446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0637.xml |
| 035 | |a (DE-627)NLM191037249 | ||
| 035 | |a (NLM)19719457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sissung, Tristan M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.11.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Thalidomide |2 NLM | |
| 650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Thordardottir, Silja |e verfasserin |4 aut | |
| 700 | 1 | |a Gardner, Erin R |e verfasserin |4 aut | |
| 700 | 1 | |a Figg, William D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 9(2009), 10 vom: 01. Dez., Seite 1058-69 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2009 |g number:10 |g day:01 |g month:12 |g pages:1058-69 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2009 |e 10 |b 01 |c 12 |h 1058-69 | ||